benserazide has been researched along with Nausea in 8 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A sixteen-week study examined the effect of Madopa and Sinemet on patients with Parkinson disease disease suffering nausea or vomiting as side-effects of levodopa therapy and compared the efficacy of the three preparations in controlling the symptoms of Parkinson disease." | 9.04 | A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson disease. ( Diamond, SG; Markham, CH; Treciokas, LJ, 1978) |
| "A sixteen-week study examined the effect of Madopa and Sinemet on patients with Parkinson disease disease suffering nausea or vomiting as side-effects of levodopa therapy and compared the efficacy of the three preparations in controlling the symptoms of Parkinson disease." | 5.04 | A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson disease. ( Diamond, SG; Markham, CH; Treciokas, LJ, 1978) |
| "Thirty patients with restless legs syndrome, who initially had all responded well to treatment with levodopa and benserazide, were studied as to the long-term effect of the drugs (at least 2 years)." | 3.68 | Long-term effect of dopaminergic drugs in restless legs. A 2-year follow-up. ( Kempi, V; von Scheele, C, 1990) |
| "5%, probably reflecting some differences in the bioavailability of the various galenical formulations, and the mean daily drug intakes were reduced from 5." | 2.68 | Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. L-Dopa Dual-Release Study Group. ( Gachoud, JP; Gasser, U; Ghika, J, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (75.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ghika, J | 1 |
| Gachoud, JP | 1 |
| Gasser, U | 1 |
| Rinne, UK | 1 |
| Birket-Smith, E | 1 |
| Dupont, E | 1 |
| Hansen, E | 1 |
| Hyyppä, M | 1 |
| Marttila, R | 1 |
| Mikkelsen, B | 1 |
| Pakkenberg, H | 1 |
| Presthus, J | 1 |
| Gilland, O | 1 |
| Diamond, SG | 1 |
| Markham, CH | 1 |
| Treciokas, LJ | 1 |
| Gerlach, J | 1 |
| von Scheele, C | 1 |
| Kempi, V | 1 |
| Boudin, G | 1 |
| Pépin, B | 1 |
| Guillard, A | 1 |
| Fabiani, JM | 1 |
| Haguenau, M | 1 |
| Barbeau, A | 1 |
| Mars, H | 1 |
| Gillo-Joffroy, L | 1 |
5 trials available for benserazide and Nausea
| Article | Year |
|---|---|
Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. L-Dopa Dual-Release Study Group.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Bensera | 1997 |
Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial.
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood Pressure; Clinical Tri | 1975 |
[Levodopa and decarboxylase inhibitors in Parkinson's disease].
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hydrazines; Lev | 1977 |
A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson disease.
Topics: Adult; Benserazide; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Fem | 1978 |
Effect of CB 154 (2-bromo-alpha-ergocryptine) on paralysis agitans compared with Madopar in a double-blind, cross-over trial.
Topics: Aged; Azides; Benserazide; Bromocriptine; Clinical Trials as Topic; Dose-Response Relationship, Drug | 1976 |
3 other studies available for benserazide and Nausea
| Article | Year |
|---|---|
Long-term effect of dopaminergic drugs in restless legs. A 2-year follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benserazide; Bromocriptine; Child; Dopamine Agents; Drug | 1990 |
[Indications and results of monoamine treatment in parkinsonian syndromes].
Topics: Aged; Arrhythmias, Cardiac; Benserazide; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Combinations; | 1972 |
Adverse clinical side effects of levodopa therapy.
Topics: Antiparkinson Agents; Arrhythmias, Cardiac; Benserazide; Carboxy-Lyases; Dihydroxyphenylalanine; Ede | 1971 |